Toxoplasmosis in cord blood transplantation recipients

Transpl Infect Dis. 2012 May 1. doi: 10.1111/j.1399-3062.2012.00735.x. [Epub ahead of print]

Toxoplasmosis in cord blood transplantation recipients

Bautista G, Ramos A, Forés R, Regidor C, Ruiz E, de Laiglesia A, Navarro B, Bravo J, Portero F, Sanjuan I, Fernández MN, Cabrera R.

Department of Hematology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

Toxoplasmosis is a devastating opportunistic infection that can affect immunocompromised patients such as cord blood transplantation (CBT) recipients. The clinical characteristics of 4 toxoplasmosis CBT patients treated at our institution are reviewed, together with 5 cases collected from the literature. The rate of toxoplasmosis in our hospital was 6% in CBT recipients and 0.2% in other types of allogeneic hematopoietic stem cell transplantation (P < 0.001). Five patients (56%) presented disseminated toxoplasmosis and 4 patients (44%) had localized infection in the central nervous system. In 5 of the 9 patients considered (56%), cytomegalovirus viral replication had been detected before the clinical onset of toxoplasmosis. Seven patients (78%) had previously developed graft-versus-host disease. All patients who exhibited disseminated disease died due to Toxoplasma infection. Pre-transplant serology was positive in 1 patient, negative in 3 patients, and not performed in another. Only 1 of these 5 patients with disseminated disease had received Toxoplasma prophylaxis with cotrimoxazole. It could be concluded that mortality in CBT patients with disseminated toxoplasmosis is unacceptably high. The negative results of serology in the majority of these cases, and its unspecific clinical presentation, makes diagnosis exceedingly difficult. Better diagnostic tests and prophylaxis strategy are needed in CBT recipients.

© 2012 John Wiley & Sons A/S.

PMID: 22548804 [PubMed - as supplied by publisher]